Metformin/rosiglitazone combination pill (Avandamet®) for the treatment of patients with Type 2 diabetes
- 11 June 2007
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 8 (9), 1353-1364
- https://doi.org/10.1517/14656566.8.9.1353
Abstract
More than 150 million people worldwide have diabetes, the prevalence of which is increasing so rapidly that the number of adults with diabetes in the world will rise to 300 million by the year 2025. In the US, ∼ 21 million people have diabetes and in some areas of the country, the prevalence is as high as 50%. The pathophysiologic hallmarks consist of insulin resistance and progressive pancreatic β-cell dysfunction. An increased metabolic demand for insulin due to increased insulin resistance usually precedes the development of hyperglycemia. At early stages, pancreatic β cells compensate for insulin resistance by hypersecretion of insulin. However, the period of β-cell compensation is followed by β-cell failure, in which the pancreas fails to secrete sufficient insulin and diabetes ensues. Biguanides and thiazolidinediones (TZDs) are two unique classes of oral antidiabetic agents that are the most commonly used medications to improve insulin sensitivity. They have no direct effect on β-cell function, although some indirect mechanisms of actions may help to preserve β-cell function or slow β-cell apoptosis. Their glucose-lowering effect results from improving insulin sensitivity in a complementary fashion: metformin reduces hepatic glucose production and TZDs increase skeletal muscle glucose use. The combination of metformin and rosiglitazone in a single pill (Avandamet®), was approved by the FDA in October 2002 for the treatment of diabetes. As insulin resistance is a pathophysiologic cornerstone of diabetes and cardiovascular disease, the use of Avandamet represents an optimal approach to the treatment of diabetes. This manuscript reviews the pharmacology, safety and benefits of the combination pill Avandamet.Keywords
This publication has 77 references indexed in Scilit:
- Thiazolidinediones for the treatment of type 2 diabetesEuropean Journal of Internal Medicine, 2007
- Diabetes, TZDs, and Bone: A Review of the Clinical EvidencePPAR Research, 2006
- Thiazolidinedione Use and Bone Loss in Older Diabetic AdultsJournal of Clinical Endocrinology & Metabolism, 2006
- Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndromeJCI Insight, 2006
- Effect of Rosiglitazone on Endothelial Function and Inflammatory Markers in Patients With the Metabolic SyndromeDiabetes Care, 2006
- Rosiglitazone/MetforminDrugs, 2005
- Potential Role of Oral Thiazolidinedione Therapy in Preserving ??-Cell Function in Type 2 Diabetes MellitusDrugs, 2005
- Current oral agents for type 2 diabetesPostgraduate Medicine, 2002
- RosiglitazoneDrugs, 1999
- Metformin improves blood lipid pattern in nondiabetic patients with coronary heart diseaseJournal of Internal Medicine, 1996